The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
Zacks · 10/13 13:45
Morgan Stanley Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $31
Morgan Stanley maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $32 to $31.
Benzinga · 10/13 12:50
Sarepta: Leading The Genomic Medicine Pack
Sarepta has a diversified portfolio of 43 programs including 27 gene therapy and 14 RNA programs. The pipeline is spread between discovery (21) and commercial (2) medicines.The current valuation for Sarepta is comparable to the group of 6 gene therapy companies acquired between 2017 and 2019.Sarepta is now included in the tracking group used to provide comps for this sector.
Seekingalpha · 10/12 14:43
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.
Zacks · 10/12 13:45
A Look At The Fair Value Of Editas Medicine, Inc. (NASDAQ:EDIT)
How far off is Editas Medicine, Inc. (NASDAQ:EDIT) from its intrinsic value? Using the most recent financial data...
Simply Wall St. · 10/10 14:55
Benzinga Pro's Top 5 Stocks To Watch For Thursday, Oct. 8, 2020: TSLA, JNJ, ROKU, IH, EDIT
Today's 5 Stock Ideas:  Tesla (TSLA) - Chairman Elon Musk confirmed after market close Wednesday Tesla's new structural battery and cells are first going to the Model Y at the Giga Berlin
Benzinga · 10/08 12:16
Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics and Other Stocks
This year’s Nobel Prize for chemistry was awarded Wednesday to the two discoverers of Crispr/Cas9, which has led to gene-editing treatments for inherited illnesses like sickle-cell anemia. · 10/07 15:04
CRISPR gene editing discovers share Nobel Prize
Emmanuelle Charpentier and Jennifer Doudna, the discoverers of a bacterial immune system called CRISPR (clustered regularly interspaced short palindromic repeats), a simple gene editing tool that has the potential to
Seekingalpha · 10/07 10:38
Hedge Funds Have Never Been This Bullish On Editas Medicine, Inc. (EDIT)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress
Insider Monkey · 10/06 23:45
These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each.
Seekingalpha · 10/03 20:21
Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of Biopharma
Neurocrine presents encouraging three-year data for Parkinson’s treatment.Avinger receives FDA approval for Ocelaris.Editas bounces on favorable CRISPR patent ruling.
Seekingalpha · 09/18 15:07
Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference
CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued a decision in an interference between the University of California, the University of Vienna, Emmanuelle Charpentier
GlobeNewswire · 09/11 12:00
Why Is Editas (EDIT) Down 17.3% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 15:32
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: Citi’s 15th Annual BioPharma Virtual Conference Panel: Innovation in Cell Therapy
GlobeNewswire · 09/04 12:00
Editas Medicine Review Plus Now - Better Choice Of PTC Therapeutics
In Late October last year we subjected Editas Medicine to an investment behavioral analysis because its developmental approach relies on genome editing.Then (before COVID-19) the analysis appeared quite promising of near-term capital gains under the discipline of TERMD portfolio management, in comparison to other biotech developers.The EDIT forecast of +20% gain was attained and pocketed in less than a month. Now, is reinvestment in EDIT as attractive again as similar biotech developer alternatives?With over 400 biotech-developer stocks available we once more use the behavior of investors – via their Yahoo Finance research-reading interests – in combing appropriate comparisons of alternatives.Enough change in institutional investment interest near-term has occurred to consider PTCT and XLRN more interesting and productive near-term capital gain alternatives instead.
Seekingalpha · 08/28 13:20
If You Had Bought Editas Medicine (NASDAQ:EDIT) Stock Three Years Ago, You Could Pocket A 65% Gain Today
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
Simply Wall St. · 08/26 16:54
Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag
The FDA bestows a Rare Pediatric Disease designation on Editas' (EDIT) experimental candidate EDIT-301, which is being developed for treating sickle cell disease.
Zacks · 08/25 16:54
Editas Scores Rare Disease Tag For EDIT-301 Sickle Cell Treatment
Editas Medicine (EDIT) has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for EDIT-301. This is an experimental, autologous cell medicine, being developed as a potentially best-in-class, durable medicine for sickle cell disease.The genome
SmarterAnalyst · 08/25 08:02
Editas Medicine nabs rare pediatric disease tag for sickle cell candidate
Seeking Alpha - Article · 08/24 14:56
3 Important Things I've Learned Reviewing ARK's ETFs
ARK Invest currently offers some of the best performing ETFs over the past five years. The five actively managed ETFs provided by ARK cover innovation, autonomous technology and robotics, next generation internet, genomics and fintech.
Seeking Alpha - Article · 08/24 14:53
Webull provides a variety of real-time EDIT stock news. You can receive the latest news about Editas Medicine through multiple platforms. This information may help you make smarter investment decisions.
About EDIT
Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).